SPECIAL NOTICE
A -- Intent to Annouce - RPP 18-01 of MCDC OTA
- Notice Date
- 9/28/2017
- Notice Type
- Special Notice
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of the Army, Army Contracting Command, ACC - NJ (W15QKN), BUILDING 10 PHIPPS RD, PICATINNY ARSENAL, New Jersey, 07806-5000, United States
- ZIP Code
- 07806-5000
- Solicitation Number
- W15QKN18Z0B9X
- Archive Date
- 12/31/2017
- Point of Contact
- Emily A. Pellegrino, Phone: 9737245855, Alexandra Trunzo, Phone: 9737244179
- E-Mail Address
-
emily.a.pellegrino2.civ@mail.mil, alexandra.m.trunzo.civ@mail.mil
(emily.a.pellegrino2.civ@mail.mil, alexandra.m.trunzo.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- This is not a Request for Prototype Proposals, but for planning purposes only. A project award will not be awarded from this announcement. The Government intends to announce one Request for Prototype Proposals (RPP 18-01) for execution of a project award(s) in support of Medical Countermeasure Systems Research and Development related to specified project requirements. The purpose of this announcement is to provide members of the Medical CBRN Defense Consortium, and industry in general, advanced notification of Government intent. On 08 April 2016, the Government entered into an Other Transaction Agreement (OTA) with one (1) consortium, the Medical CBRN Defense Consortium (MCDC), in support of Medical Countermeasure Systems related research and development prototype projects. It is the intent of the Government to make project award(s) to member(s) of the MCDC as a result of member project proposals submitted via the Request for Prototype Proposals process. RPP 18-01 The Government anticipates four (4) projects for white papers and full proposals to be solicited via W15QKN-16-9-1002 - consisting of the following: 1. Rapid Single-molecule-based Diagnostic Platform Assessment of Pathogen Susceptibility to Anti-microbial Agent. 2. Development of Multiplex Molecular Diagnostics Based on CRISPR-Cas and other Synthetic Biology Approaches. 3. Enhanced Circulatory Stability and GMP manufacturing of Phosphotriesterase (PTE) / Organophosphorus Hydrolase (OPH) variants as prophylaxis against a broad-spectrum of Organophosphorus Nerve Agents (OPNAs). 4. Late Discovery and Development of Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve Agents. In order to obtain more information regarding the above projects, you must be a member of the Medical CBRN Defense Consortium (MCDC), www.medcbrn.org. For more information regarding membership or general questions to the MCDC, contact Michael Stebbins, at 843-760-4094 or mcdc@ati.org. Contracting Office Address: Army Contracting Command - New Jersey Building 9 Phipps Road Picatinny Arsenal, New Jersey 07806-5000 United States
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/904e3d94bb638580ad4a3bb84287a884)
- Record
- SN04700159-W 20170930/170928233206-904e3d94bb638580ad4a3bb84287a884 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |